Skip to content

A Randomized Controlled Clinical Trial of Cordyceps militaris Beverage on the Immune Response

A Randomized Controlled Clinical Trial of Cordyceps militaris Beverage on the Immune Response

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20231003001
Enrollment
40
Registered
2023-10-03
Start date
2022-11-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male and female healthy subjects Cordyceps militaris, Healthy subjects, NK cell, Cytokine, Immunomodulation

Interventions

Male received single oral dose of functional beverages from submerged fermentation of Cordyceps militaris (FCM),Male received placebo,Female received single oral dose of functional beverages from subm
MFCM,MPB,FFCM,FPB

Sponsors

National Innovation Agency (NIA)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Male and female adult participants aged 25-60 during the screening test. 2) No history of hypersensitivity or idiosyncratic reactions to drugs or herbal products. 3) Willing to participate in the project throughout the research program.

Exclusion criteria

Exclusion criteria: 1) Participants diagnosed with immune-mediated disease, nervous system disorders, cardiovascular disease, or liver or kidney disease. 2) Participants diagnosed with chronic health problems such as hypertension, diabetes, or renal failure, etc. 3) A body mass index (BMI) greater than 29.9 or less than 18 kg/m2. 4) Participants who were pregnant or lactating or intended to become pregnant during the trial period. 5) Participants who, within two weeks, ingested a drug or functional food that may affect the immunomodulatory effect of the test product 6) Participants who had an alanine transaminase (ALT) or aspartate transaminase (AST) plasma level more than three times the guideline of the organization.

Design outcomes

Primary

MeasureTime frame
Immune Response at 4 and 8 weeks after end of the intervention T cell absolute count, B cell absolute count, Natural Killer (NK) cell absolute count, and Cytokine levels

Secondary

MeasureTime frame
Safety at 4 and 8 weeks after end of the intervention Hematological, metabolic, and safety indexes

Countries

Thailand

Contacts

Public ContactAtcharaporn Ontawong

University of Phayao

atcharaporn.on@up.ac.th0953651593

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026